Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

22. september 2026 opdateret af: CorMedix Therapeutics

A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult And Adolescent Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)

This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

200

Fase

  • Fase 3

Udvidet adgang

Ikke længere tilgængelig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Liz Hurlburt, Chief Clinical Strategy & Operations Officer
  • Telefonnummer: 908-517-9500
  • E-mail: lhurlburt@cormedix.com

Studiesteder

    • California
      • Los Angeles, California, Forenede Stater, 90024
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
    • Florida
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital - GCRC
        • Kontakt:
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
      • Maywood, Illinois, Forenede Stater, 60153
        • Rekruttering
        • Loyola University Medical Center
        • Kontakt:
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Health Care
        • Kontakt:
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21205
        • Rekruttering
        • Johns Hopkins Clinical Research Unit
        • Kontakt:
        • Kontakt:
    • Minnesota
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68198-3285
        • Rekruttering
        • University of Nebraska Medical Center
        • Kontakt:
          • David F Mercer, MD, PhD, FRCS(C)
          • Telefonnummer: 402-559-6955
          • E-mail: dmercer@unmc.edu
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10032
      • New York, New York, Forenede Stater, 10029
      • New York, New York, Forenede Stater, 10016
        • Ikke rekrutterer endnu
        • NYU Grossman School of Medicine
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Trukket tilbage
        • Duke University Hospital
    • Ohio
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic Foundation
        • Kontakt:
        • Kontakt:
          • Jessica Sosio, DO
          • Telefonnummer: 216-442-2416
          • E-mail: sosioj@ccf.org
    • Pennsylvania
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37212-1150
        • Rekruttering
        • Vanderbilt Center for Human Nutrition
        • Kontakt:
        • Kontakt:
    • Texas
      • Sugarland, Texas, Forenede Stater, 77478
    • Ankara
      • Altındağ, Ankara, Tyrkiet (Türkiye), 06230
        • Rekruttering
        • Hacettepe University Hospitals
        • Kontakt:
        • Kontakt:
      • Yenimahalle, Ankara, Tyrkiet (Türkiye), 06560
        • Rekruttering
        • Hacettepe University Hospitals
        • Kontakt:
        • Kontakt:
      • Çankaya, Ankara, Tyrkiet (Türkiye), 06800
        • Rekruttering
        • Ankara Bilkent City Hospital
        • Kontakt:
        • Kontakt:
      • Çankaya, Ankara, Tyrkiet (Türkiye), 06230
        • Rekruttering
        • Ankara University Ibni Sina Research and Application Hospital
        • Kontakt:
        • Kontakt:
    • Istanbul
      • Istanbul, Istanbul, Tyrkiet (Türkiye), 34093

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

12 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

  1. Participants who are resident within study site's country.

  2. Participants who are male or female, aged ≥12 years at the time of consent.

  3. Participants must sign and provide informed consent. For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.

  4. Participants who have a tunneled/non-tunneled CVC or peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.

  5. Participants who require long-term (>3 Months) TPN based on the investigator assessments.

  6. Participants who require TPN for at least 3 days per week, of which 2 days have to be parenteral nutrition (PN).

  7. Participants who have a minimum of a 4-hour CLS dwelling time and are willing to lock all lumens at a minimum of every 7 days.

  8. Participants who are clinically stable, in the opinion of the investigator, for at least 4 weeks prior to enrollment.

  9. Participants who are able and willing to be trained or have a caregiver who is willing and able to be trained on the instillation, aspiration of DefenCath or heparin, and to maintain a daily diary.

    Male or female participants:

  10. Women of childbearing potential (WOCBP; see Section 4.5.1) must have a negative pregnancy test at screening (i.e., the participant is not pregnant); not be lactating; and use an acceptable method of contraception including but not limited to, abstinence, bilateral tubal ligation, vasectomized partner, a barrier method (diaphragm or condom), Depo-Provera, intrauterine device, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the program until at least 30 days after the last DefenCath CLS instillation. (NOTE: The participant must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).

  11. Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms with spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last DefenCath CLS instillation.

  12. Participants who comply with all study procedures and follow-up evaluations.

Exclusion Criteria:

  1. Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
  2. Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
  3. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
  4. Any participant with a secondary CVC in addition to the primary TPN line.
  5. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator [tPA]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
  6. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
  7. Any participant using any type of antimicrobial-coated or heparin-coated catheter.
  8. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.
  9. Any participant with a congenitally lethal condition or a life expectancy of less than 6 months.
  10. Any participant with documented history of an atrial thrombus or known hypercoagulable state.
  11. Any participant with an open, non-healing skin ulcer.
  12. Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.
  13. Any participant with neutropenia with an absolute neutrophil count <500 cells/μL
  14. Any participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count <500 cells/μL that occured in the past 4 weeks.
  15. Any participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
  16. Any participant taking other medication with known systemic drug interaction with citrate, taurolidine or heparin.
  17. Any participant anticipating receiving an intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive an intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
  18. Any participant who is pregnant or lactating.
  19. Any participant receiving continuous TPN (infusion over 24 hours).
  20. Any participant with any medical conditions that render them unable to, or unlikely to complete the study or would interfere with optimal participation in the study or produce significant risk to participant.
  21. Any participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Styring

Heparin

Eksperimentel: DefenCath®

for central venous catheter installation use

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI, but fail to complete the 12-month follow-up period of the study.

Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Compare the safety profile of DefenCath for use as a Catheter Lock Solution (CLS) in adult and adolescent participants receiving Total Parenteral Nutrition (TPN) through a Central Venous Catheter (CVC) to the control of heparin CLS

Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Incidence of changes in laboratory evaluations, vital signs, or physical exam findings
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Compare the safety profile of DefenCath for use as a CLS in adult and adolescent participants receiving TPN through a CVC to the control of heparin CLS

Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. maj 2025

Primær færdiggørelse (Anslået)

1. januar 2028

Studieafslutning (Anslået)

1. januar 2028

Datoer for studieregistrering

Først indsendt

15. januar 2025

Først indsendt, der opfyldte QC-kriterier

6. februar 2025

Først opslået (Faktiske)

12. februar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NUTRI-GUARD

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Sharibg if protocol and ICF, pending FDA approval of this indication

IPD-delingstidsramme

Pending FDA Approval

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner